Clinical Trial Search

Primary: Proportion of Confirmed Responses With Ixazomib Citrate Alone (Arm A [Closed]), Ixazomib Citrate With Dexamethasone (Arms B + C), or With Dexamethasone and…

Primary: The Difference Between Touch Detection Thresholds From the Sensorimotor Evaluation at Baseline and After 10 Weeks of Induction Therapy. — 0.00; 0.06; 0.08; 0.13 mN…

Primary: Change in Drug Use — .02; .50; .09; .34 Episodes of drug use

Primary: Change in Cardiorespiratory Fitness — -0.15; 0.12; 0.22 Liters of oxygen/min — p=0.006

Primary: Proportion of Patients Alive and Free of Respiratory Failure at Day 28 — 152; 71 participants — p=0.216

Primary: Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral Creatine — 1.49; 1.42 Ratio

Primary: Treatment Evaluation Inventory-Short Form (TEI-SF) — 3.62; 4.00; 3.94; 3.69 units on a scale

Primary: Change in Balance Performance — 0.52; 0.42; 0.51; 0.48 degrees per second

Primary: Change in Cerebral Blood Flow (CBF) at Baseline Between Obstructive Sleep Apnea Syndrome (OSAS) and Controls — 184; 209 percentage of change from baseline

Primary: Change From Baseline in Body Weight — -1.41; -0.91; -1.66 kg — p=0.7870

Primary: Brown Adipose Tissue Volume — 53.1; 20.6 mL

Primary: Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) — 11; 32; 32; 0 Participants

Primary: Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) Score — -41.5; -35.8 score on a scale

Primary: Accuracy of BGMS Compared to the Reference Analyzer - Fingerstick Blood Test — 127 Participants

Primary: Proportion of Study Subjects Able to Titrate up to the Maximum Tolerated Dose — 6 Participants